

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 1 of 12	Effective Date: 1/14/16 3/1/19

Commented [CC1]: Minor administrative updates – due for 3 year review

1. POLICY STATEMENT:

~~An Overall Principal~~ A DF/HCC Investigator (~~PI~~) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that must be adhered to in order to properly conduct this research within DF/HCC.

2. BACKGROUND:

The Food and Drug Administration (FDA) medical device regulations establish specific responsibilities of sponsors for ensuring

- (1) The proper conduct of research for submission to the FDA, and;
- (2) The protection of the rights and welfare of subjects involved in this research.

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

3. RESPONSIBLE PERSONNEL:

- 3.1. ~~Overall Principal~~ DF/HCC Investigator (~~PI~~), who holds the IDE and/or is the Sponsor

4. DEFINITIONS:

4.1. **Medical Device:** An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component part, or accessory, which is (1) recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (3) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. *Investigational device* means any device, including a transitional device, which is the object of an investigation.

4.2. **Investigation:** A clinical investigation or research involving one or more subjects to determine the safety or effectiveness of a device.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 2 of 12	Effective Date: 1/14/16 3/1/19

- 4.3. **Investigator:** An individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used, involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team.
- 4.4. **Monitor:** When used as a noun, means the individual designated by a sponsor or contract research organization to oversee the progress of an investigation. The monitor may be an employee or a sponsor, or an employee or consultant to a contract research organization. *Monitor*, when used as a verb, means to oversee an investigation.
- 4.5. **Sponsor:** A person who initiates, but does not actually conduct, the investigation, that is, the investigational device is administered, dispensed, or used under the immediate direction of another individual. A person other than an individual that uses one or more of its employees to conduct an investigation that it has initiated is a sponsor, not a sponsor-investigator, and the employees are investigators.
- 4.6. **Sponsor-investigator:** An individual who both initiates and actually conducts, alone or with others, an investigation, that is, under whose immediate direction the investigational device is administered, dispensed, or used. The term does not include any person other than an individual. The obligations of a sponsor-investigator under this part include those of an investigator and those of a sponsor.
- 4.7. **Sponsor Regulatory File:** The compilation of specific essential document for a clinical investigation. The documents that individually and collectively permit evaluation of the conduct of the research and the quality of the data produced. These documents serve to demonstrate the compliance of the sponsor and monitor with the applicable research standards and all regulatory requirements.
- 4.8. **Subject:** A human who participates in an investigation, either as an individual on whom or on whose specimen an investigational device is used or as a control. A subject may be in normal health or may have a medical condition or disease.
- 4.9. **IDE Number:** This is generally a 6-digit number (ex. 060025) beginning with a letter (for example: G) that the Food and Drug Administration (FDA) assigns the investigational device being used in a specific clinical trial. It references the product(s) used under a specific IDE application. This number must be referenced on all correspondence to the FDA.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 3 of 12	Effective Date: 1/14/16 3/1/19

4.10. **Significant risk (SR):** Under 21 CFR 812.3(m), an SR device means an investigational device that:

- Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;
- Is purported or represented to be for use supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;

- Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or

- Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

4.11. **Non-significant risk (NSR):** A NSR device study does not meet the definition for a SR device study. The sponsor must comply with the abbreviated IDE requirements.

4.12. **Investigational Device Exemptions:** Sponsor and investigators of certain device studies are allowed to use an investigational device in a clinical study in order to collect safety and effectiveness data. The exemption only applies to investigations in which 510(k) products are being used in accordance with the labeling cleared by the FDA.

5. POLICY:

5.1. Determination of Risk:

[5.1.1.](#) The Sponsor of an investigational device study is responsible for the initial risk determination and presenting it to the Institutional Review Board (IRB).

The risk determination should be based on the proposed use of a device in an investigation and not on the device alone.

~~5.1.1.~~[5.1.2.](#) The IRB must review the sponsor's determination for every investigational medical device study and modify the determination if the IRB disagrees with the sponsor.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 4 of 12	Effective Date: 1/14/16 3/1/19

[5.1.1.1-5.1.2.1.](#) If the FDA has already made the risk determination for the study, the agency's determination is final.

[5.1.2-5.1.3.](#) For assistance with risk determination, the FDA Office of Device Evaluation (ODE) should be contacted. Correspondence with the ODE should be made in writing and include:

[5.1.2.1-5.1.3.1.](#) A request for a written response from the ODE

[5.1.2.2-5.1.3.2.](#) A description of the device

[5.1.2.3-5.1.3.3.](#) The clinical protocol or detailed summary of the clinical protocol including the potential risks to subjects

[5.1.2.4-5.1.3.4.](#) Rationale for initial risk determination by the Sponsor / Principal Investigator

[5.1.3-5.1.4.](#) The Sponsor's risk determination submission must include an Investigational Plan comprised of:

[5.1.3.1-5.1.4.1.](#) Purpose: The name and intended use of the device and the objectives and duration of the investigation.

[5.1.3.2-5.1.4.2.](#) Protocol: A written protocol describing the methodology to be used and an analysis of the protocol demonstrating that the investigation is scientifically sound.

[5.1.3.3-5.1.4.3.](#) Risk analysis: A description and analysis of all increased risks to which subjects will be exposed by the investigation; the manner in which these risks will be minimized; a justification for the investigation; and a description of the patient population, including the number, age, sex, and condition.

[5.1.3.4-5.1.4.4.](#) Description of device: A description of each important component, ingredient, property, and principle of operation of the device and of each anticipated change in the device during the course of the investigation.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 5 of 12	Effective Date: 1/14/16 3/1/19

[5.1.3.5](#)[5.1.4.5](#). Monitoring procedures: The sponsor's written procedures for monitoring the investigation and the name and address of any monitor.

[5.1.3.6](#)[5.1.4.6](#). Labeling: Copies of all labeling for the device.

[5.1.3.7](#)[5.1.4.7](#). Consent materials: Copies of all forms and informational materials to be provided to subjects to obtain informed consent.

[5.1.3.8](#)[5.1.4.8](#). IRB information: A list of the names and locations of all IRBs that have been or will be asked to review the investigation and a certification of any action taken by any of those IRBs with respect to the investigation.

[5.1.3.9](#)[5.1.4.9](#). Other institutions: The name and address of each institution at which a part of the investigation may be conducted.

5.2. Responsibilities and Reporting:

5.2.1. Sponsor Responsibilities for Significant Risk Device Studies (SR):

5.2.1.1. SR device studies must be conducted in accordance with the full IDE requirements within and may not commence until 30 days following Sponsor's submission of an IDE application to the FDA.

5.2.1.2. The sponsor must submit an IDE application to the FDA and obtain the agency's approval of the study.

5.2.1.3. The sponsor must advise its investigators about the SR status and obtain their agreement to comply with the applicable regulations governing such studies. Sponsors should provide the IDE number and/or a copy of the IDE approval letter to the IRB when requested. All communications with investigators are maintained in the Sponsor Regulatory File.

5.2.1.4. Sponsors may send their SR device study to an IRB for review before the IDE application is approved by the FDA. However, the FDA cautions that an SR device study may not begin until the FDA approves the IDE.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 6 of 12	Effective Date: 1/4/4631/19

5.2.1.5. Once an IDE application is approved, the following requirements must be met in order to conduct the investigation in compliance with the IDE regulation:

- 5.2.1.5.1. **Labeling:** The device must be labeled in accordance with the labeling provisions of the IDE regulation and must bear the statement "CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use." A copy of the approved label and all updates are maintained in the Sponsor Regulatory File.
- 5.2.1.5.2. **Distribution:** Investigational devices can only be distributed to qualified investigators. Records for distribution are maintained in the Sponsor Regulatory File.
- 5.2.1.5.3. **Informed Consent:** The sponsor will provide a template of the informed consent document to each investigator. The investigator will obtain approval from their local IRB. Any changes to the informed consent document will be reviewed and consideration given to updating the overall consent for the trial. This assessment must be maintained as an official record. All communications and informed consent documents are maintained by the sponsor in the Sponsor Regulatory File. Each subject must be provided with and sign an informed consent document before being enrolled in the research.
- 5.2.1.5.4. **Monitoring:** All investigations must be properly monitored, as outlined in the Sponsor developed monitoring plan that was submitted to and approved by the FDA, to protect the human subjects and assure compliance with approved protocols.
- 5.2.1.5.5. **Prohibitions:** Commercialization, promotion, and misrepresentation of an investigational device and prolongation of the study are prohibited.
- 5.2.1.5.6. **Records and Reports:** Sponsors and investigators are required to maintain specified records and make reports to investigators, IRBs, and the FDA.
- 5.2.1.5.7. Once an IDE is in effect, the Sponsor must adhere to the following periodic IDE submission requirements set by the FDA.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 7 of 12	Effective Date: 1/14/16 3/1/19

The local IRB must receive and review all information submitted to the FDA.

5.2.1.5.7.1.*IDE Supplement: Changes in investigational plan* are those changes that are likely to have significant effect on the scientific soundness of the research design and/or validity of the data resulting from the research, such as: changes in indication; changes in type or nature of study control; changes in primary endpoint; changes in method of statistical evaluation; early termination; expanding the research by increasing the number of investigational sites or number of subjects. These changes are submitted prior to implementation

5.2.1.5.7.2.*IDE Supplement: Developmental change* is a change to the basic principles of operation of a device. This change is submitted within 5 working days of the change.

5.2.1.5.7.3.*IDE Supplement: Changes in clinical protocol* are changes to the protocol that do not affect the validity of the data or the risk to benefit relationship in the approved protocol, scientific soundness of the investigational plan or the safety and welfare of the subjects. Examples of these types of changes include modifications of inclusion/exclusion criteria; increasing frequency of data collection; inclusion of additional observations or measurements; and modifying secondary endpoints. These changes are submitted within 5 working days of the change.

5.2.1.5.7.4.*IDE Supplement: New facilities* may be submitted at one time or at 6 month intervals.

5.2.1.5.7.5.*Informed consent not obtained* must be submitted within 5 working days of learning of the occurrence.

5.2.1.5.7.6.*Protocol deviation* must be submitted prior to the protocol change or deviation if it affects study integrity or subject safety.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 8 of 12	Effective Date: 1/14/16 3/1/19

5.2.1.5.7.7. *Unanticipated adverse effect report* must be submitted within 10 working days of receiving notification. Refer to www.fda.gov/medwatch.

5.2.1.5.7.8. *Current investigator list* must be submitted at 6 month intervals.

5.2.1.5.7.9. *Progress report* must be submitted annually.

5.2.1.5.7.10. *Study completion notification* must be submitted within 30 days of study completion.

5.2.1.5.7.11. *Final report* must be submitted within six (6) months of study completion.

5.2.1.5.7.12. *Study termination due to unreasonable risk* must be submitted with five (5) working days of study termination and no later than fifteen (15) working days after receiving notice of effect.

5.2.1.5.7.13. *Withdrawal of approval* must be submitted within 5 working days of receiving the withdrawal notice from the IRB.

5.2.1.5.7.14. *Recall of device* must be submitted within 30 days of occurrence.

5.2.1.5.7.15. *Financial disclosure information* must be submitted at the time of change and for one (1) year following study completion.

5.2.2. Sponsor Responsibilities for Nonsignificant Risk Device Studies (NSR):

5.2.2.1. If the sponsor identifies a study as NSR, the sponsor must provide the reviewing IRB an explanation of its determination and should provide any other information that may help the IRB in evaluating the risk of the study. For example, a description of the device, reports of prior investigations with the device, the proposed investigational plan, subject selection criteria, and other information the IRB may need.

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 9 of 12	Effective Date: 1/14/16 3/1/19

5.2.2.2.NSR device studies do not have to have an IDE application approved by the FDA.

5.2.2.2.1. An NSR device study may start at the institution as soon as the IRB reviews and approved the study without prior approval from the FDA.

5.2.2.2.2. Sponsors and IRBs do not have to report IRB approval of an NSR device study to the FDA. This means that an IRB may approve and NSR device study and an investigator may conduct the study without the FDA knowing about it.

5.2.2.2.3. If an IRB determines that a device is a significant risk device (SR), and the sponsor had proposed that the IRB consider the device not to be significant risk device, the sponsor shall submit to the FDA a report of the IRB's determination within five (5) working days after the sponsor learns of the IRB's determination.

5.2.2.3.The sponsor also must comply with the following requirements for NSR device studies:

5.2.2.3.1. Labeling: The device must be labeled in accordance with the labeling provisions of the IDE regulation and must bear the statement "CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use" A copy of the approved label and all updates are maintained in the Sponsor Regulatory File.

5.2.2.3.2. IRB Approval: The sponsor must obtain and maintain Investigational Review Board (IRB) approval throughout the investigation as a nonsignificant risk device study.

5.2.2.3.3. Informed Consent: The sponsor will provide a template of the informed consent to each investigator. The investigator will obtain approval from their local IRB. Any changes to the informed consent should be reviewed and consideration given to updating the overall consent for the trial. This assessment must be maintained as an official record. All communications and consents are maintained by the sponsor in the Sponsor Regulatory File. The

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 10 of 12	Effective Date: 1/14/2019

sponsor must assure that investigators obtain and document informed consent from each subject.

- 5.2.2.3.4. Monitoring: All investigations must be properly monitored, as outlined in the Sponsor developed monitoring plan that was submitted to and approved by the FDA, to protect the human subjects and assure compliance with approved protocols.
- 5.2.2.3.5. Records and Reports: Sponsors are required to maintain specific records and make certain reports as required by the IDE regulation.
- 5.2.2.3.6. Investigator Records and Reports: The sponsor must assure that participating investigators maintain records and make reports as required.
- 5.2.2.3.7. Prohibitions: Commercialization, promotion, test marketing, misrepresentation of an investigational device, and prolongation of the study are prohibited.

5.2.3. Sponsor Responsibilities for IDE Exempt Device Studies:

5.2.3.1. Studies exempt from the IDE regulation include:

- 5.2.3.1.1. The device must be used in accordance with its labeling
- 5.2.3.1.2. If it is a diagnostic device, it must comply with the labeling requirements in §809.10(c)
- 5.2.3.2. Consumer preference testing, testing of a modification, or testing of a combination of devices if the device(s) are legally marketed device(s), that is, the devices have an approved PMA, cleared Premarket Notification 510(k), or are exempt from 510(k)] AND if the testing is not for the purpose of determining safety or effectiveness and does not put subjects at risk.

Note: IRB submission of Sponsor risk determination is required.

5.2.4. Sponsor Adverse Event Responsibilities:

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 11 of 12	Effective Date: 1/14/19

5.2.4.1.A sponsor who determines that an unanticipated adverse device effect presents an unreasonable risk to subjects must terminate all investigations or parts of the investigations presenting that risk as soon as possible for SR and NSR trials.

5.2.4.1.1. Termination must occur no later than five (5) working days after the sponsor makes this determination and no later than fifteen (15) working days after the sponsor first received notice of the effect.

5.2.4.1.2. A sponsor may not resume a terminated investigation without IRB approval.

5.2.4.2.If a non significant risk (NSR) study was terminated for unanticipated adverse device effects, the sponsor must also obtain FDA approval to continue.

5.2.5. Emergency Use Devices:

5.2.5.1.An investigator may treat a patient with an unapproved medical device in an emergency situation if he/she concludes the following:

5.2.5.1.1. The patient has a life-threatening condition that needs immediate treatment

5.2.5.1.2. No generally acceptable alternative treatment for the condition exists.

5.2.5.1.3. Because of the immediate need to use the device, there is no time to use existing procedures to get FDA approval for the use.

5.2.5.1.4. All emergency uses of an unapproved medical device must be reported to the IRB within five (5) working days.

5.2.5.1.5. All essential regulatory documents are maintained in the protocol specific regulatory file.

6. APPLICABLE REGULATIONS & GUIDELINES:

21 CFR 50 – Protection of Human Research Subjects

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18

**DANA-FARBER / HARVARD CANCER CENTER
POLICIES FOR HUMAN SUBJECT RESEARCH**

TITLE: Responsibilities of the Sponsor Conducting Research Involving a Device		
POLICY #: RCO-101	Page: 12 of 12	Effective Date: 1/444631/19

21 CFR 54 – Financial Disclosure by Clinical Investigators
21 CFR 56 – Institutional Review Boards
21 CFR 809 – In-Vitro Diagnostic Products
21 CFR 812 – Investigational New Device Exemptions
FDA Industry Guidelines and Information Sheets
FDA Compliance Policy Guidance Programs: 7348.809, 7348.810, and 7348.811

7. RELATED REFERENCES:

International Conference on Harmonisation – E6
Guide to Human Research Activity

8. RELATED RESOURCES:

Medwatch Form FDA 3500

Version: 4
Effective Date: 1/31/19
Last Reviewed Date: 11/13/18